Sign in
CompletedEarly phase 1

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Key facts

Who runs it
Yale University
Where
Hartford, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
78 people enrolled
Started
17 May 2022
Ended
31 May 2026
Type of study
Interventional, 4 groups
Treatments tested
  • Mavoglurant (AFQ056)
  • Placebo
Record updated
24 September 2026

Who can take part

Age
18 years to 45 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Ages 18-45 years
  • Estimated full-scale IQ>70
  • Individual can cooperate with all study procedures
  • No history of neurological disorder (e.g., epilepsy)
  • No major medical condition (e.g., cancer)
  • No history of significant head trauma
  • Stable medication treatment 6 weeks prior to study enrollment
  • Negative urine drug and breathe alcohol test at time of MRI scan
  • Negative urine pregnancy test at time of MRI scan
  • No MR contra-indications (e.g., in-body metal implant, severe claustrophobia)
  • No contra-indications to study drug

Who cannot take part

  • A current diagnosis of: a) Alcohol use disorder, if severe (AUD, mild or moderate OK if no craving, tolerance, and withdrawal 3 months prior to interview) b) Substance use disorder
  • Women not on an effective form of birth control/contraception or abstinent during time of study visits to prevent exposure of the investigational drug to suspected fetus
  • A diagnosis of any psychotic disorder, or current mood or anxiety disorders under DSM-V, using the SCID-V-RV psychiatric interview
  • Report of psychotic disorder in a 1º relative
  • Auditory or visual impairment that interferes with test-taking
  • Prenatal exposure to alcohol plus currently meeting criteria for features of fetal alcohol syndrome
  • Presence or history of neurosurgery or any neurologic illness that may affect brain physiology (e.g., epilepsy, Multiple Sclerosis), including focal brain lesion seen on structural MRI (all structural scans are read by a board certified radiologist)
  • A current major medical condition (e.g. cancer, heart failure)
  • Not speaking English fluently or being a non-native English speaker, or being educated in a primary language other than English > grade 1
  • Intellectual Disability (Full Scale IQ<70)
  • Traumatic brain injury with loss of consciousness > 30 minutes or concussion in last 30 days
  • Current pregnancy (all females will be tested with urine screens on the day of MRI)
  • Current substance use with the exception of marijuana (THC), provided last use of THC was 24+ hours before visit (All participants will receive a urine screen for the presence of marijuana, cocaine, opiates and a breath screen to detect the presence of alcohol)
  • Inability to comprehend the consent form appropriately
  • Inability to cooperate with study procedures
  • Other specific fMRI exclusions include metal devices, clips or fragments in body (orbital xray performed if needed)

Where in United States

  • Hartford HospitalHartford, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

The 4 groups in the trial

  • FHP; Mavoglurant-PlaceboTreatment being tested

    Family History Positive (FHP) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.

    Treatment: Mavoglurant (AFQ056) and Placebo

  • FHP; Placebo-MavoglurantTreatment being tested

    Family History Positive (FHP) or alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.

    Treatment: Mavoglurant (AFQ056) and Placebo

  • FHN; Mavoglurant-PlaceboTreatment being tested

    Family History Negative (FHN) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.

    Treatment: Mavoglurant (AFQ056) and Placebo

  • FHN; Placebo-MavoglurantTreatment being tested

    Family History Negative (FHN) for alcoholism will be given a single dose of placebo then AFQ056 (200 mg) in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.

    Treatment: Mavoglurant (AFQ056) and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
24 September 2026